| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm | 4.70 mm |
| Cash burn (monthly) | 82.67 k | (no burn) | 3.24 mm | 3.13 mm | 3.74 mm | 2.56 mm |
| Cash used (since last report) | 420.19 k | n/a | 16.48 mm | 15.89 mm | 18.99 mm | 13.03 mm |
| Cash remaining | 4.28 mm | n/a | -11.77 mm | -11.19 mm | -14.29 mm | -8.32 mm |
| Runway (months of cash) | 51.8 | n/a | -3.6 | -3.6 | -3.8 | -3.2 |
| 13F holders | Current |
|---|---|
| Total holders | 70 |
| Opened positions | 28 |
| Closed positions | 6 |
| Increased positions | 21 |
| Reduced positions | 11 |
| 13F shares | Current |
|---|---|
| Total value | 34.03 bn |
| Total shares | 18.30 mm |
| Total puts | 253.00 k |
| Total calls | 164.70 k |
| Total put/call ratio | 1.5 |
| Largest owners | Shares | Value |
|---|---|---|
| FBIO Fortress Biotech | 6.90 mm | $19.61 mm |
| Armistice Capital | 4.46 mm | $14.27 bn |
| Vanguard | 1.90 mm | $6.07 bn |
| CVI Investments | 636.96 k | $1.69 mm |
| Susquehanna International | 478.81 k | $1.53 bn |
| Geode Capital Management | 445.11 k | $1.43 bn |
| Kestra Advisory Services | 329.28 k | $1.05 bn |
| MS Morgan Stanley | 286.99 k | $918.37 mm |
| BlackRock | 285.25 k | $912.81 mm |
| GS The Goldman Sachs Group, Inc. | 196.13 k | $627.60 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Feb 25 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 18,500 | 0.00 | 6,222,249 |
| 10 Feb 25 | James F Oliviero III | COMMON STOCK | Sell | Dispose S | No | No | 3.15 | 10,331 | 32.54 k | 3,775,019 |
| 7 Feb 25 | James F Oliviero III | COMMON STOCK | Sell | Dispose S | No | No | 3.41 | 9,233 | 31.48 k | 3,785,350 |
| 6 Feb 25 | Gray William Garrett | COMMON STOCK | Sell | Dispose S | No | No | 3.67 | 74,110 | 271.98 k | 1,458,644 |
| 30 Jan 25 | James F Oliviero III | COMMON STOCK (RESTRICTED) | Grant | Acquire A | No | No | 0 | 1,500,000 | 0.00 | 3,794,583 |
| 30 Jan 25 | Gray William Garrett | COMMON STOCK (RESTRICTED) | Grant | Acquire A | No | No | 0 | 500,000 | 0.00 | 1,532,754 |
